Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Down 8.5% – Time to Sell?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’s stock price dropped 8.5% during trading on Tuesday . The company traded as low as $13.59 and last traded at $13.60. Approximately 160,285 shares traded hands during trading, a decline of 51% from the average daily volume of 329,598 shares. The stock had previously closed at $14.87.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Wedbush reissued an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Canaccord Genuity Group reiterated a “buy” rating and issued a $26.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Canaccord Genuity Group upgraded Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. BMO Capital Markets lowered their price target on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. Finally, Morgan Stanley cut their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $21.14.

Y-mAbs Therapeutics Stock Performance

The firm’s 50-day simple moving average is $14.03 and its two-hundred day simple moving average is $13.12. The stock has a market cap of $519.10 million, a price-to-earnings ratio of -21.46 and a beta of 0.68.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The business had revenue of $18.46 million for the quarter, compared to the consensus estimate of $23.38 million. During the same period last year, the firm earned ($0.18) earnings per share. Equities research analysts expect that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the transaction, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at approximately $449,514. The trade was a 14.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Thomas Gad sold 30,000 shares of Y-mAbs Therapeutics stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $12.97, for a total value of $389,100.00. Following the transaction, the insider now owns 67,681 shares in the company, valued at $877,822.57. This trade represents a 30.71 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 100,000 shares of company stock valued at $1,338,100. 22.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Large investors have recently made changes to their positions in the stock. Squarepoint Ops LLC increased its holdings in Y-mAbs Therapeutics by 143.4% during the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock worth $1,527,000 after purchasing an additional 74,452 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Y-mAbs Therapeutics in the 3rd quarter valued at approximately $178,000. Millennium Management LLC lifted its stake in Y-mAbs Therapeutics by 23.8% in the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after acquiring an additional 67,233 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Y-mAbs Therapeutics by 15.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after acquiring an additional 65,732 shares during the last quarter. Finally, Ameritas Investment Partners Inc. grew its stake in shares of Y-mAbs Therapeutics by 39.9% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock worth $60,000 after acquiring an additional 1,056 shares in the last quarter. Institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.